The Cape Town company that has signed with Pfizer and BioNTech to produce their Covid vaccine for distribution in Africa is planning a new €130m (about R2bn) facility that could produce up to 500-million doses a year by 2026, and is in talks with development finance institutions (DFIs) to fund this.
The Biovac Institute, which was SA's only vaccine manufacturer until Aspen entered the market with the Johnson & Johnson (J&J) Covid vaccine earlier this year, is to start producing the Pfizer-BioNTech vaccine by the end of this year, ramping up to 100-million doses a year in terms of its agreement with the two companies...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.